{"id":3894,"date":"2025-03-31T18:11:52","date_gmt":"2025-03-31T18:11:52","guid":{"rendered":"https:\/\/kidneydiseaseclinic.net\/kdc\/daptomycin-txt\/"},"modified":"2025-03-31T18:11:52","modified_gmt":"2025-03-31T18:11:52","slug":"daptomycin-txt","status":"publish","type":"post","link":"https:\/\/kidneydiseaseclinic.net\/kdc\/daptomycin-txt\/","title":{"rendered":"Daptomycin.txt"},"content":{"rendered":"<h1> Daptomycin<\/h1>\n<p><H3>  CLINICAL USE <\/H3><br \/>\nAntibacterial agent<H3> DOSE IN NORMAL RENAL FUNCTION  <\/H3>4\u20136 mg\/kg once daily for 7 to 14 days depending on indication<H3>  PHARMACOKINETICS    <\/H3><LI> Molecular weight &amp;nbsp  &amp;nbsp &amp;nbsp &amp;nbsp &amp;nbsp &amp;nbsp &amp;nbsp &amp;nbsp  &amp;nbsp &amp;nbsp &amp;nbsp &amp;nbsp &amp;nbsp :1620.7<\/li>\n<li>  %Protein binding  &amp;nbsp &amp;nbsp &amp;nbsp  &amp;nbsp  &amp;nbsp  &amp;nbsp &amp;nbsp &amp;nbsp &amp;nbsp &amp;nbsp &amp;nbsp &amp;nbsp &amp;nbsp :90\u201392<\/li>\n<li>  %Excreted unchanged in urine &amp;nbsp &amp;nbsp : Approximately 50%<\/li>\n<p><LI> Volume of distribution (L\/kg) &amp;nbsp &amp;nbsp &amp;nbsp :0.092\u20130.104<\/li>\n<p><LI>half-life \u2013 normal\/ESRD (hrs)&amp;nbsp &amp;nbsp &amp;nbsp :8.1\u20139\/29.41<H3>  DOSE IN RENAL IMPAIRMENT <\/H3> <H4>GFR (mL\/MIN)<\/H4>30\u201350 Dose as in normal renal function&lt;30 4 mg\/kg every 48 hours<H3> DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES  <\/H3><LI> CAPD  &amp;nbsp &amp;nbsp &amp;nbsp  &amp;nbsp &amp;nbsp &amp;nbsp &amp;nbsp &amp;nbsp:Not dialysed. Dose as in GFR&lt;30 mL\/min<\/p>\n<li> HD &amp;nbsp  &amp;nbsp &amp;nbsp  &amp;nbsp &amp;nbsp  &amp;nbsp &amp;nbsp &amp;nbsp &amp;nbsp &amp;nbsp :Not dialysed. Dose as in GFR&lt;30 mL\/min<LI>HDF\/high flux  &amp;nbsp :Dialysed. Dose as in GFR&lt;30 mL\/min<LI> CAV\/VVHD  <\/LI>\/VVhdFSlightly dialysed. 4\u20136 mg\/kg every 48 hours2 <H3> IMPORTANT DRUG INTERACTIONS  <\/H3>Potentially hazardous interactions with other drugsWarfarin: Monitor INR when on  daptomycinCiclosporin: increased risk of myopathy \u2013  try to avoid concomitant useLipid-regulating drugs: increased risk of  myopathy with fibrates and statins \u2013 try to avoid concomitant use<H3> ADMINISTRATION  <\/H3><H4> Reconstition<\/H4>7 mL sodium chloride 0.9% or water for  injection to give a solution of 50 mg\/mL<H4>  Route  <\/H4><H4> IV infusion  <\/H4> <H4>  Rate of Administration  <\/H4>Over 30 minutes <H4>Comments<\/H4>Once reconstituted, stable for 12 hours  at room temperature and 48 hours refrigeratedAdd to 50 mL sodium chloride 0.9% before  administration. Stable for 12 hours at room temperature or 24 hours refrigeratedIncompatible with dextrose solutions Compatible with solutions containing  aztreonam, ceftazidime, ceftriaxone, gentamicin, fluconazole, levofloxacin, dopamine, heparin and lidocaine<H4>  OTHER INFORMATION  <\/H4>May cause renal impairment Vials do not contain any bacteriostatic or  fungiostatic agentsCompany advises to administer post  dialysisMonitor creatinine phosphokinase levels,  muscle pain or weaknessIncreased risk of myopathy in severe renal  failure due to increased daptomycin levels15% of dose is removed by 4 hours of  haemodialysis and 11% over 48 hours by peritoneal dialysisTherapeutic concentrations of daptomycin  are unlikely due to low PD clearance of drug therefore systemic use for peritonitis is unlikely to work<br \/>\n","protected":false},"excerpt":{"rendered":"<p>Daptomycin CLINICAL USE Antibacterial agent DOSE IN NORMAL RENAL FUNCTION<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[7],"class_list":["post-3894","post","type-post","status-publish","format-standard","hentry","category-blog","tag-post-by-auto-php"],"_links":{"self":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/3894","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/comments?post=3894"}],"version-history":[{"count":0,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/3894\/revisions"}],"wp:attachment":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/media?parent=3894"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/categories?post=3894"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/tags?post=3894"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}